Compare PGR & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGR | GSK |
|---|---|---|
| Founded | 1937 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | 66841 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.4B | 108.7B |
| IPO Year | 2008 | N/A |
| Metric | PGR | GSK |
|---|---|---|
| Price | $190.11 | $50.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 2 |
| Target Price | ★ $238.85 | N/A |
| AVG Volume (30 Days) | 2.5M | ★ 3.3M |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | ★ 6.93% | 3.40% |
| EPS Growth | ★ 33.54 | N/A |
| EPS | ★ 4.80 | N/A |
| Revenue | ★ $87,671,000,000.00 | N/A |
| Revenue This Year | $2.25 | $6.99 |
| Revenue Next Year | $7.33 | $4.19 |
| P/E Ratio | $40.65 | ★ $32.75 |
| Revenue Growth | ★ 16.32 | N/A |
| 52 Week Low | $191.75 | $35.45 |
| 52 Week High | $289.78 | $61.70 |
| Indicator | PGR | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 34.19 | 40.71 |
| Support Level | N/A | $49.99 |
| Resistance Level | $208.47 | $51.46 |
| Average True Range (ATR) | 4.11 | 0.80 |
| MACD | -0.69 | 0.23 |
| Stochastic Oscillator | 0.76 | 46.79 |
Progressive underwrites private and commercial auto insurance and specialty lines; it has almost 27 million personal auto policies in force and is one of the largest auto insurers in the United States. Progressive markets its policies through independent insurance agencies in the US and Canada and directly via the internet and telephone. Its premiums are split between the agent and the direct channel. The company also offers commercial auto policies and entered homeowners insurance through an acquisition in 2015.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.